AstraZeneca近日宣布,其创新药物Fasenra(通用名:benralizumab)已经获得美国食品和药物管理局(FDA)的扩展批准,可用于6至11岁患有严重嗜酸粒细胞性哮喘(Severe Eosinophilic Asthma,SEA)的儿科患者作为附加维持治疗。 这项新的适应症批准是基于开放标签的3期临床试验TATE的结果,以及先前在成人和青少年患者中进行的良好对照...
原文出处:New FASENRA® data from the MELTEMI extension trial confirm long-term safety and efficacy in severe eosinophilic asthma for up to five years
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
当前,阿斯利康也正在开发benralizumab用于慢性阻塞性肺病(COPD)的治疗。 原文出处:Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
April 11th, AstraZeneca’s FASENRA® (benralizumab) is approved by the US FDA for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype. FASENRA is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attract...
FASENRA is an add-on maintenance treatment for patients 6 and older with severe eosinophilic asthma.See more. Not for sudden breathing problems. This Site is for US Patients FASENRA treats: Eosinophilic Asthma Approved use Patient Information ...
Approximately half of patients with EGPA have adult-onset severe eosinophilic asthma (SEA) and often have sinus and nasal symptoms.3,8,9FASENRA is only the second biologic approved to treat this disease.4,5 FASENRA is currently approved as an add-on maintenance treatment for SEA in more than...
Fasenra (benralizumab) is an injectable monoclonal antibody that may be used as add-on therapy to treat severe eosinophilic asthma in adults and children aged 6 years and older. Fasenra is also approved to treat eosinophilic granulomatosis with polyangiitis (EGPA) in adults....
with other asthma medicines for the maintenance treatment of asthma in people 6 years and older whose asthma is not controlled with their current asthma medicines. FASENRA is not used to treat sudden breathing problems. to treat people 18 years and older with eosinophilic granulomatosis with polyangi...